Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Enaksha R Wickremsinhe"'
Autor:
Anne H. Dantzig, Everett J. Perkins, Enaksha R. Wickremsinhe, James J. Starling, Gregory P. Donoho, Robert L. Shepard, Sara Durland–Busbice, Susan E. Pratt
PDF file - 112K, Supplementary Figure 2 - in vivo study body weights
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b26de16f0ee5d751321264d9d15621d
https://doi.org/10.1158/1535-7163.22498848
https://doi.org/10.1158/1535-7163.22498848
Autor:
Anne H. Dantzig, Everett J. Perkins, Enaksha R. Wickremsinhe, James J. Starling, Gregory P. Donoho, Robert L. Shepard, Sara Durland–Busbice, Susan E. Pratt
PDF file - 316K, Supplementary Figure 1 - in vivo study body weights
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71b531576d023873277f8bbc6e15fa91
https://doi.org/10.1158/1535-7163.22498851
https://doi.org/10.1158/1535-7163.22498851
Autor:
Anne H. Dantzig, Everett J. Perkins, Enaksha R. Wickremsinhe, James J. Starling, Gregory P. Donoho, Robert L. Shepard, Sara Durland–Busbice, Susan E. Pratt
PDF file - 72K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08b0837c46c6fb9854d5f51893366d9a
https://doi.org/10.1158/1535-7163.22498845.v1
https://doi.org/10.1158/1535-7163.22498845.v1
Publikováno v:
Bioanalysis
The COVID-19 pandemic challenged pharmaceutical and bioanalytical communities at large, in the development of vaccines and therapeutics as well as supporting ongoing drug development efforts. Existing processes were challenged to manage loss of staff
Autor:
Lisa B Lee, Enaksha R Wickremsinhe
Publikováno v:
Bioanalysis. 13:711-724
Aim: Bioanalytical methods undergo many revisions and modifications throughout drug development to meet the objectives of the study and development program. Results: Validated LC–MS/MS methodology used to quantify abemaciclib and four metabolites i
Autor:
Kenneth C. Cassidy, Christopher D. Payne, Scott M. Hynes, Enaksha R Wickremsinhe, Yingying Guo
Publikováno v:
Xenobiotica. 50:793-804
The disposition and metabolism of prexasertib, a CHK-1 inhibitor was characterised over a 120 h period following a single 170-mg intravenous dose of [14C]prexasertib (50 µCi) to 6 patients with adv...
Publikováno v:
Bioanalysis. 12(13)
[ ]of writing, it is unclear whether this will result in a permanent change in how blood sampling for clinical trials and routine healthcare are performed, although it seems unlikely that the progression of these sampling technologies will be slowed
Publikováno v:
Bioanalysis. 11:1015-1038
There is growing interest in the implementation of microsampling approaches for the quantitation of circulating concentrations of analytes in biological samples derived from nonclinical and clinical studies involved in drug development. This interest
Publikováno v:
Bioanalysis. 11:619-628
There is continuing interest in the development and application of various microsampling technologies for drug development. The AAPS bioanalytical community microsampling subgroup and the European Bioanalysis Forum conducted a survey of their members
Publikováno v:
Bioanalysis. 13(5)